drugset

drugset / Trial / NCT03836001

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

NCT03836001 ↗

Phase 2 Completed 28 enrolled Stanford University Epidermolysis Bullosa Research Partnership · collab Vyne Therapeutics Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.

Timeline

Start: 2019-04-18
Primary completion: 2021-12-06
Completion: 2022-06-24

Publications

Chiou AS, Choi S, Barriga M, Dutt-Singkh Y, Solis DC, Nazaroff J, Bailey-Healy I, Li S, Shu K, Joing M, Kwon P, Tang JY. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial. J Am Acad Dermatol. 2020 Jun;82(6):1415-1421. doi: 10.1016/j.jaad.2019.09.014. Epub 2019 Sep 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Serlopitant	Small molecule	5 mg	Oral

Indications